相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Daniel L. Suzman et al.
LIVER INTERNATIONAL (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
A. Rotte et al.
ANNALS OF ONCOLOGY (2018)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. A. Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab
Ioanna Parisi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2016)
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Jeffrey S. Weber et al.
ONCOLOGIST (2016)
Toxicity management of immunotherapy for patients with metastatic melanoma
Helena Linardou et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Risk of Drug-Induced Liver Injury From Tumor Necrosis Factor Antagonists
Einar S. Bjornsson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Ipilimumab in the treatment of prostate cancer
Zachary Reese et al.
FUTURE ONCOLOGY (2015)
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management
Roberta Elisa Rossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
CANCER (2013)
Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
Einar S. Bjornsson et al.
GASTROENTEROLOGY (2013)
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim et al.
INVESTIGATIONAL NEW DRUGS (2013)
Ipilimumab-induced acute severe colitis treated by infliximab
Cecile Pages et al.
MELANOMA RESEARCH (2013)
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease
Chiara van Casteren-Messidoro et al.
JOURNAL OF CROHNS & COLITIS (2012)
Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
Charlotte Lemech et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2012)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
James D. Lord et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Infliximab-related hepatitis: discussion of a case and review of the literature
Stefano Mancini et al.
INTERNAL AND EMERGENCY MEDICINE (2010)
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
David R. Minor et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. L. Johnston et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Giao Q. Phan et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis
M Esteve et al.
GUT (2004)
分享论文
